(Q48260461)

10 February 2018

title

Adaptive-optimal design in PET occupancy studies (English)

1 reference

10 February 2018

author

Roger N. Gunn

4

1 reference

10 February 2018

Andrew C. Hooker

7

1 reference

10 February 2018

author name string

S Zamuner

1

1 reference

10 February 2018

V L Di Iorio

2

1 reference

10 February 2018

J Nyberg

3

1 reference

10 February 2018

V J Cunningham

5

1 reference

10 February 2018

R Gomeni

6

1 reference

10 February 2018

language of work or name

English

0 references

publication date

24 March 2010

1 reference

10 February 2018

Clinical Pharmacology & Therapeutics

published in

1 reference

10 February 2018

volume

87

1 reference

10 February 2018

issue

5

1 reference

10 February 2018

page(s)

563-571

1 reference

10 February 2018

Using positron emission tomography to facilitate CNS drug development

cites work

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.9

Time course of central nervous dopamine-D2 and 5-HT2 receptor blockade and plasma drug concentrations after discontinuation of quetiapine (Seroquel) in patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.9

Pharmacokinetics and time-course of D(2) receptor occupancy induced by atypical antipsychotics in stabilized schizophrenic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.9

MAO-A inhibition in brain after dosing with esuprone, moclobemide and placebo in healthy volunteers: in vivo studies with positron emission tomography

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.9

Pharmacokinetic-pharmacodynamic modeling of the antinociceptive effect of buprenorphine and fentanyl in rats: role of receptor equilibration kinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.9

Peripheral and central H1 histamine receptor occupancy by levocetirizine, a non-sedating antihistamine; a time course study in the guinea pig.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.9

A PET study of dopamine D2 and serotonin 5-HT2 receptor occupancy in patients with schizophrenia treated with therapeutic doses of ziprasidone

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.9

Serotonin transporter occupancy of five selective serotonin reuptake inhibitors at different doses: an [11C]DASB positron emission tomography study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.9

Human positron emission tomography studies of brain neurokinin 1 receptor occupancy by aprepitant

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.9

Time course of dopamine D2 receptor occupancy by clozapine with medium and high plasma concentrations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.9

Significant dissociation of brain and plasma kinetics with antipsychotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.9

The time course of binding to striatal dopamine D2 receptors by the neuroleptic ziprasidone (CP-88,059-01) determined by positron emission tomography.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.9

Modeling of brain D2 receptor occupancy-plasma concentration relationships with a novel antipsychotic, YKP1358, using serial PET scans in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.9

Simultaneous population optimal design for pharmacokinetic-pharmacodynamic experiments

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.9

Optimal design of a population pharmacodynamic experiment for ivabradine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.9

Development and implementation of the population Fisher information matrix for the evaluation of population pharmacokinetic designs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.9

An evaluation of population D-optimal designs via pharmacokinetic simulations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.9

Antipsychotic dosing in preclinical models is often unrepresentative of the clinical condition: a suggested solution based on in vivo occupancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.9

Estimate the time varying brain receptor occupancy in PET imaging experiments using non-linear fixed and mixed effect modeling approach.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.9

Population pharmacokinetic analysis for simultaneous determination of B (max) and K (D) in vivo by positron emission tomography

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.9

A quantitative model for the in vivo assessment of drug binding sites with positron emission tomography

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.9

Mechanism-based PK/PD modeling of the respiratory depressant effect of buprenorphine and fentanyl in healthy volunteers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.9

Approaches to handling pharmacodynamic baseline responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.9

Optimal design for model discrimination and parameter estimation for itraconazole population pharmacokinetics in cystic fibrosis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.9

POPED, a software for optimal experiment design in population kinetics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.9

Simultaneous optimal experimental design on dose and sample times

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.9

The use of imaging in the early development of neuropharmacological drugs: a survey of approved NDAs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.9

inferred from DOI database lookup

7 January 2021

based on heuristic

Optimal adaptive design in clinical drug development: a simulation example

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.9

inferred from DOI database lookup

7 January 2021

based on heuristic

Robust Population Pharmacokinetic Experiment Design

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.9

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1038/CLPT.2010.9

1 reference

10 February 2018

1 reference

10 February 2018